Ad Header



The Pulse of the Pharmaceutical Industry

Novartis says biosimilar rituximab accepted for review by FDA

Written by: | | Dated: Tuesday, September 12th, 2017


ZURICH (Reuters) – Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

Rituximab, made by Novartis’ unit Sandoz, has been proposed as a biosimilar to Roche’s reference medicine Rituxan, Novartis said in a statement.

Rituximab was approved in Europe in June, Novartis said.


Reporting by Silke Koltrowitz


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation